Serum 1,25-dihydroxyvitamin D concentration in hypophosphatemic vitamin D-resistant rickets.

Abstract

Fasting serum 1 alpha, 25-dihydroxyvitamin D [1,25-(OH)2D] levels were measured in 3 groups of hypophosphatemic vitamin D-resistant rickets (VDRR) patients; those untreated; those treated with vitamin D and phosphate; and those treated with 1,25-(OH)2D3 and phosphate. In the untreated patients, the mean 1,25-(OH)2D level was higher than in our age-matched control group. Except for one at 66 pg/ml, individual values were however within normal limits. Long term vitamin D2 therapy was accompanied by a slight but significant decrease in 1,25-(OH)2D concentrations; nonetheless the levels remained within the normal range. In the third group of patients, the concentration of 1,25-(OH)2D rose to supranormal levels when sampling was done 1-3 hours after administration of the hormone, decreasing rapidly to levels below that of normal subjects when the specimens were collected 12-24 hours later. Our data show that an alteration of the vitamin D activation pathway is unlikely to be part of the pathogenic mechanism underlying the VDRR condition.

• Authors: E E Delvin, F H Glorieux
• Journal: Calcified tissue international (Calcif Tissue Int) Vol. 33 Issue 2 Pg. 173-5 ( 1981) ISSN: 0171-967X [Print] United States
• PMID: 6260313 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Dihydroxycholecalciferols
• Ergocalciferols
• Hydroxycholecalciferols
• Parathyroid Hormone
• Phosphates
• Alkaline Phosphatase
• Calcitriol

Topics

• Adolescent
• Alkaline Phosphatase (blood)
• Calcitriol
• Child
• Child, Preschool
• Dihydroxycholecalciferols (blood)
• Ergocalciferols (therapeutic use)
• Female
• Humans
• Hydroxycholecalciferols (blood)
• Hypophosphatemia, Familial (blood, drug therapy)
• Male
• Parathyroid Hormone (blood)
• Phosphates (blood, therapeutic use)